Furthermore, the use of DAC in combination with the BCL2 inhibitor Venetoclax as shown promising efficacy in individual T-ALL patients in relapse [51, 52] Indeed, there are several ongoing clinical trials investigating the combination of DAC with Venetoclax for high-risk and relapse/refractory T-ALL. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.